In the course of our studies on differential gene expression in NASH patients with severe fibrosis, we observed upregulation of adipocyte enhancer binding protein 1 (AEBP1), also known as aortic carboxypeptidase (ACLP) compared to NASH patients with no histological evidence of fibrosis [9]. The gene discussed is AEBP1; the disease is metabolic dysfunction-associated steatohepatitis.